ImmunoGen Announces IMGN901 Data (NASDAQ:IMGN)

ImmunoGen, Inc (NASDAQ:IMGN) have reported the clinical data of their IMGN901 product candidate which will be used for the treatment of Merkel cell carcinoma (MCC).
The Company mentioned that the meaningful evidence of anti-cancer activity has been noted in limited number of patients who are suffering from MCC and who have received IMGN901. The findings were reported at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, MA, and suggest development for metastatic MCC could be a potential registration path for IMGN901. MCC is an aggressive neuroendocrine cancer of the skin that typically occurs on the head or neck, most often in individuals of European ancestry. However, each year there are about 1400 cases of MCC diagnosed in the United States each year and the trend for MCC is increasing every year.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. IMGN901 made by ImmunoGen is designed to kill cancer cells that express CD56, a protein. It consists of a CD56-binding antibody with a potent cancer-cell killing agent, DM1, attached to it using an engineered linker. In other words, IMGN901 is a potential treatment for MCC, small-cell lung cancer, multiple myeloma, ovarian cancers and other CD56+ tumors. Now that ImmunoGen has received encouraging results from their Phase 1 of IMGN901, they have decided to ahead with Study 002 and Study 003 to find the future of this clinical compound wholly-owned by ImmunoGen.